Trust Co. of Vermont raised its position in shares of C.R. Bard, Inc. (NYSE:BCR) by 2.4% during the second quarter, according to its most recent filing with the SEC. The fund owned 5,742 shares of the medical instruments supplier’s stock after buying an additional 136 shares during the period. Trust Co. of Vermont’s holdings in C.R. Bard were worth $1,815,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Dimensional Fund Advisors LP boosted its stake in C.R. Bard by 1.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 235,925 shares of the medical instruments supplier’s stock valued at $53,003,000 after buying an additional 2,748 shares during the period. Israel Discount Bank of New York GFN purchased a new stake in C.R. Bard during the fourth quarter valued at $481,000. UBS Asset Management Americas Inc. boosted its stake in C.R. Bard by 3.5% in the fourth quarter. UBS Asset Management Americas Inc. now owns 267,451 shares of the medical instruments supplier’s stock valued at $60,087,000 after buying an additional 9,134 shares during the period. Perigon Wealth Management LLC boosted its stake in C.R. Bard by 14.6% in the fourth quarter. Perigon Wealth Management LLC now owns 2,566 shares of the medical instruments supplier’s stock valued at $631,000 after buying an additional 327 shares during the period. Finally, Teachers Advisors LLC boosted its stake in C.R. Bard by 3.5% in the fourth quarter. Teachers Advisors LLC now owns 134,481 shares of the medical instruments supplier’s stock valued at $30,213,000 after buying an additional 4,500 shares during the period. Hedge funds and other institutional investors own 85.32% of the company’s stock.
C.R. Bard, Inc. (NYSE BCR) traded down 0.24% during mid-day trading on Tuesday, hitting $318.18. The company’s stock had a trading volume of 907,452 shares. The stock has a market cap of $23.12 billion, a P/E ratio of 41.77 and a beta of 0.59. The company’s 50 day moving average is $318.45 and its 200-day moving average is $280.37. C.R. Bard, Inc. has a 52-week low of $203.63 and a 52-week high of $323.27.
C.R. Bard (NYSE:BCR) last posted its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.84 by $0.08. The business had revenue of $979.70 million during the quarter, compared to the consensus estimate of $976.53 million. C.R. Bard had a net margin of 14.99% and a return on equity of 48.70%. The company’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.54 earnings per share. On average, equities analysts predict that C.R. Bard, Inc. will post $11.81 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Friday, August 4th. Investors of record on Monday, July 24th were paid a dividend of $0.26 per share. The ex-dividend date of this dividend was Thursday, July 20th. This represents a $1.04 dividend on an annualized basis and a dividend yield of 0.33%. C.R. Bard’s payout ratio is currently 13.67%.
Several equities analysts have issued reports on the company. Zacks Investment Research raised C.R. Bard from a “hold” rating to a “buy” rating and set a $351.00 target price on the stock in a research report on Tuesday, June 13th. BMO Capital Markets downgraded C.R. Bard from an “outperform” rating to a “market perform” rating and set a $245.00 price target for the company. in a report on Tuesday, April 25th. Morgan Stanley downgraded C.R. Bard from an “overweight” rating to an “equal weight” rating in a report on Monday, April 24th. BidaskClub downgraded C.R. Bard from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 19th. Finally, Jefferies Group LLC reiterated a “hold” rating on shares of C.R. Bard in a report on Thursday, August 3rd. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, one has given a buy rating and one has issued a strong buy rating to the company’s stock. C.R. Bard presently has a consensus rating of “Hold” and an average target price of $285.67.
About C.R. Bard
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with our FREE daily email newsletter.